Skip to main content

Table 2 Transition probabilities applied in the model

From: Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Parameter

Probability

Reference

Discontinuation SLIT (5-grass tablet)

Year 1

0.29

[27]

Year 2

0.28

[27]

Discontinuation SCIT (allergoid mix)

Year 1

0.41

[27]

Year 2

0.34

[27]

Developing asthma with symptomatic treatment

0.0046

[28]

Relative risk developing asthma (AIT vs. symptomatic treatment)

0.505

[29,30]

All population mortality*

0.00046

[31]

Asthma mortality*

0.00069

[32]

  1. *Probabilities represent mortality at start of the analysis (29 years).
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us